Overview

• Eli Lilly has increased the UK list price of Mounjaro by up to 170 percent, prompting stockpiling by private users and growing interest in switching to alternatives such as Wegovy.
• The company says it is working with pharmacies and private providers on arrangements to keep out-of-pocket costs lower than the new list prices.
• Labour MP Carolyn Harris, who says she lost more than eight stone on Mounjaro, has written to Health Secretary Wes Streeting urging action to keep the treatment affordable for patients.
• NHS England’s rollout remains tightly limited and uneven, with BMJ data showing fewer than half of commissioning bodies prescribing in line with guidance, and clinicians warning of black-market risks for those shut out.
• Eli Lilly reported phase‑3 results for its oral pill Orforglipron showing roughly 10–12 percent average weight loss and says the UK could be among the first markets in 2026 subject to regulatory approval, with expectations it will be easier to manufacture and distribute.